Society of Dermatology Physician Assistants

In a session presented at the SDPA Fall Conference, Karan Lal, DO, spoke on the topic of GLP-1 agonist drugs for weight loss and their connection to dermatology.

This Q&A interview with Trickett highlights various topics, including collaboration between PAs and physicians, pipeline news, and topical steroid withdrawal (TSW).

This segment of Maloney’s interview at the SDPA Fall Conference discussed off-label uses of JAK inhibitors and other treatment news in dermatology.

Maloney speaks in this interview at the SDPA Fall Conference about off-label uses of JAK inhibitors in dermatology.

Renata Block spoke at the 2025 SDPA Fall Conference about her session on the use of artificial intelligence tools in clinical practice.

The SDPA president, Sarah Vicari, spoke at the 2025 SDPA Fall Conference about the conference and its significance.

This segment of Goff’s SDPA Fall 2025 interview features a discussion of dietary changes and sunscreen use as a means to improve skin health.

In this interview at SDPA Fall 2025, Goff highlights several takeaways from her session on lifestyle and diet choices among patients in the dermatology space.

In a session presented at the 2025 SDPA Fall Conference, a review was given of common genetic syndromes with cutaneous manifestations.

At the 2025 SDPA Fall Conference, Laura Bush, DMSc, PA-C, presented the next iteration of an IMID and Obesity bootcamp session.

This preview of the 2025 SDPA Fall Dermatology Conference highlights different sessions and interviews covered by HCPLive.

Findings highlight the ongoing burden of generalized pustular psoriasis and suggest patients may benefit from targeted biologic therapies like the FDA-approved spesolimab.

In ARRECTOR, patients reported symptom relief and improved quality of life as early as week 2, with strong tolerability and safety through week 8.

Phase 3 trials have shown low rates of serious adverse events with ruxolitinib cream in pediatric and adult patients with atopic dermatitis and non-segmental vitiligo.

In this session at SDPA, Griffith and Sebat review clinically relevant articles from the prior 12 months from the top dermatology journals.

Check out insights from SDPA 2025 on eczema, alopecia, vitiligo, burnout, and JAK inhibitor workups—key tips to improve dermatology care.

In the BE BRIGHT trial presented at SDPA 2025, patients receiving continuous bimekizumab therapy maintained high PASI 90 and PASI 100 response rates over 5 years.

This 4-year data highlights dupilumab’s efficacy among children under the age of 12 with atopic dermatitis.

At SDPA 2025, Theodore Rosen, MD, discussed various psychological disorders, including delusions of parasitosis, excoriation disorder, dermatitis artefacta, and others.

Maria Hordinsky, MD, spoke at SDPA regarding her talk highlighting a variety of clinical pearls for spotting scarring alopecia early.

At SDPA 2025, Gordon presented on the future of dermatology, discussing current drugs being evaluated for atopic dermatitis, psoriasis, and hidradenitis suppurativa.

In her SDPA interview, Maria Hordinsky, MD, spoke about her session regarding clinical pearls for clinicians seeking to spot alopecia early in patients.

At SDPA 2025, Spizuoco discussed how trichoscopic signs like black dots, yellow dots, and exclamation hairs guide treatment decisions.

This interview segment with Scherer highlights additional takeaways from his SDPA 2025 talk, covering clues for clinicians to identify different interdigital foot infections.

In this interview at SDPA, Scherer provides an overview of foot web space infections, fungal versus bacterial infections, and more.

At SDPA 2025, Cotter highlights clinical patterns in alopecia areata that may respond better, or worse, to JAK inhibition and shares his approach to systemic therapy.

This presentation, covered at SDPA, features a discussion by Ginette Okoye, MD, who highlights diagnostic challenges among even experienced clinicians.

At SDPA 2025, Mangin emphasized the importance of wood lamp use, JAK inhibitors, and phototherapy in managing vitiligo and preventing relapse.

Hope Cook, PA-C, speaks in this interview at SDPA about strategies for clinicians seeking to overcome burnout in their careers.